Midazolam
Approved · EMAAlso known as Nayzilam, Versed, Midazolam Hydrochloride, Midazolamum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults.BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have… Show full indicationShow less
Treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults.BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy.For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. See section 4.2.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
The Safety of Driving in Patients After Minor Surgery With Monitored Anesthesia Care
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Annals of emergency medicine2
- The Journal of pharmacology and experimental therapeutics2
- Anesthesia and analgesia1
- Chest1
- Gastrointestinal endoscopy1
- Nature communications1
- Ramakrishnan S2
- Reddy DS2
- Singh T2
- Wu X2
- Abrahao A1
- Akulian J1
- Aubert I1
- Barish CF1
- Advanced Clinical Research Institute1
- Advocate Christ Medical Center1
- Borland-Groover Clinic1
- Department of Laboratory Medicine and Pathobiology1
- Department of Neuroscience and Experimental Therapeutics and Institute of Pharmacology and Neurotherapeutics1
- Duke University Medical Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Midazolam, with 4 overlapping disease areas.
Studied across 7 of the same disease areas as Midazolam in the shared literature.
Studied across 4 of the same disease areas as Midazolam in the shared literature.
Studied across the same disease area as Midazolam in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.